Evidence map›Paper›PMID 40962832›Full record

ArticleMolecular psychiatry2026

Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analyses.

Nermine Laaboub, Frederik Vandenberghe, Nicolas Ansermot, Marianna Piras, Setareh Ranjbar, Dusan Petrovic, Giorgio Pistis, Sophie Vandenberghe-Dürr, Marie-Pierre F Strippoli, Pedro Marques-Vidal and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Nermine Laaboub *Unit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. nermine.laaboub@gmail.com.ORCID http://orcid.org/0000-0001-8029-2418
Frederik Vandenberghe *Unit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Nicolas Ansermot *Unit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.ORCID http://orcid.org/0000-0001-8350-9416
Marianna Piras *Unit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.ORCID http://orcid.org/0009-0001-5579-0199
Setareh RanjbarPsychiatric Epidemiology and Psychopathology Research Center, Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Prilly, Switzerland.ORCID http://orcid.org/0000-0002-0238-2976
Dusan PetrovicCentre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Giorgio PistisPsychiatric Epidemiology and Psychopathology Research Center, Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Prilly, Switzerland.ORCID http://orcid.org/0000-0002-4525-4608
Sophie Vandenberghe-DürrDivision of Immunology and Allergology, Department of Medicine, University Hospitals of Geneva, Geneva, Switzerland.
Marie-Pierre F StrippoliPsychiatric Epidemiology and Psychopathology Research Center, Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Prilly, Switzerland.ORCID http://orcid.org/0000-0003-3053-484X
Pedro Marques-VidalDepartment of Medicine, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-4548-8500
Belen PonteDivision of Nephrology, Geneva University Hospitals, Geneva, Switzerland.
Menno PruijmService of Nephrology and Hypertension, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Bruno VogtDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Franziska GammaLes Toises Psychiatry and Psychotherapy Center, Lausanne, Switzerland.
Armin von GuntenService of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.ORCID http://orcid.org/0000-0001-7852-3803
Kerstin Jessica PlessenService of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Philippe ConusService of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Séverine CrettolUnit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.ORCID http://orcid.org/0000-0003-3790-7194
Peter VollenweiderDepartment of Medicine, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Martin PreisigPsychiatric Epidemiology and Psychopathology Research Center, Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Prilly, Switzerland.ORCID http://orcid.org/0000-0001-5689-4259
Murielle BochudCentre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Chin B EapUnit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. chinbin.eap@unil.ch.ORCID http://orcid.org/0000-0002-5439-0230

Funding

GlaxoSmithKline foundation (GSK) 3200B0-105993GlaxoSmithKline foundation (GSK) 3200B0-118308
6 · The paper itself

Abstract

Caffeine metabolic ratios (CMR) following monitored caffeine intake are the gold standard to probe cytochrome P450 (CYP) 1A2 activity, which metabolizes antipsychotics like clozapine and olanzapine. Given caffeine's ubiquity, we tested whether random CMR from dietary caffeine were associated with (1) clinical, genetic, and epigenetic factors linked to CYP1A2 activity; (2) plasma concentrations of clozapine and olanzapine; and (3) psychotropic treatment response. First, we analyzed two population-based studies (CoLaus|PsyCoLaus, N = 4898; SKIPOGH, N = 2054) to investigate random CMR associations with clinical, genome-wide, and epigenome-wide factors associated with CYP1A2 activity. Second, in psychiatric cohorts, we tested CMR associations with dose-normalized plasma concentrations (C/D) of clozapine (N = 164) and olanzapine (N = 222) and with psychotropic treatment response, including hospital admission risk (N = 1019) and prolonged stays (N = 1349). CMR were positively associated with age, CYP1A2 inducers including smoking, and negatively with female sex. CMR were negatively associated with clozapine C/D, explaining up to 14.9% of the variance; over six-fold the variance explained by genetic factors. A one-unit increase in CMR was associated with a 26% increased likelihood of hospital admission (p = 0.002) and reduced short-stay chance by 11% (p < 10

Indexed as

CaffeineClozapineCytochrome P-450 CYP1A2AdultAntipsychotic AgentsDose-Response Relationship, DrugEpigenesis, GeneticFemaleGenome-Wide Association StudyHumansMaleMiddle AgedOlanzapineSchizophreniaAntipsychotic AgentsCaffeineClozapineCYP1A2 protein, humanCytochrome P-450 CYP1A2Olanzapine

Identifiers

PMID40962832
PMCPMC12916320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.